Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
HRTX Stock — Heron Therapeuti
Heron Therapeuti (HRTX)
Updated October 16, 2026.
HRTX is a Stock. Total return is -99.9% over the past 39.1 years.
Heron Therapeutics is a commercial-stage biotechnology company developing and commercializing therapies that enhance medical care, primarily focused on nausea and vomiting prevention in cancer patients and post-operative settings. The company's marketed products include SUSTOL and CINVANTI for chemotherapy-related nausea and vomiting, along with pipeline candidates utilizing its proprietary Biochronomer drug delivery technology. This company does not currently have an established distribution program.
HRTX performance
Price and return data through 2026-10-16.
Total return is -99.9% over the past 39.1 years. Over the past year its total return — price change plus distributions reinvested — is -72.2%. Its deepest 1-year drawdown was 81.9%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 13.6% | — |
| 3M | -24.2% | — |
| 6M | -61.6% | — |
| YTD | -72.2% | — |
| 1Y | -72.2% | — |
| 2Y CAGR | — | -56.10% |
| 3Y CAGR | — | -20.90% |
| 5Y CAGR | — | -49.10% |
| 10Y CAGR | — | -31.40% |
| Since inception (39.1 years) | -99.9% | -17.20% |
HRTX key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 08/26/1987
- Distribution frequency
- None
- Last close
- $0.36 (as of 2026-10-16)
- Market cap
- $68,536,683
- Average volume
- 1725691.0
- Beta
- 1.625
- Payout ratio
- 0.0%
- Forward P/E
- 46.9484
- EPS
- $-0.18
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
HRTX risks and drawbacks
The deepest 1-year drawdown on record here is 81.9%.
Who may consider HRTX — and who may not
It is a weaker fit for investors who need monthly cash flow (HRTX does not currently distribute). This is educational context, not a recommendation to buy or sell.
More on HRTX
Frequently asked questions
Does HRTX pay monthly?
No. HRTX does not currently distribute.
When does HRTX pay a dividend?
HRTX does not currently distribute.
How has HRTX performed?
Total return is -99.9% over the past 39.1 years. Over the past year its total return — price change plus distributions reinvested — is -72.2%. Its deepest 1-year drawdown was 81.9%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.